Cardiac Biomarkers And Association With Subsequent Cardiomyopathy And Mortality Among Adult Survivor

Given that childhood cancer survivors exposed to cardiotoxic therapies are at significant cardiovascular risk, researchers sought to analyze the use of cardiac biomarkers to identify the risk of future cardiomyopathy and mortality. N‐terminal pro–B‐type natriuretic peptide (NT‐proBNP) and cardiac troponin T (cTnT) were evaluated in 1,213 adults 10 or more years from a childhood cancer diagnosis; 786 were subjected to anthracycline chemotherapy and/or chest‐directed radiation therapy (RT). NT‐proBNP and cTnT were abnormal in 22.5% and 0.4%, respectively, at a median age of 35.5 years (interquartile range, 29.8‐42.5 years). Abnormal NT-proBNP values were prevalent and those at elevated risk for future cardiomyopathy were reported among survivors who were subjected to cardiotoxic therapy but did not have a history of cardiomyopathy or current systolic dysfunction.

​

Source